DelveInsight’s “CLK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the CLK Inhibitor, historical and Competitive Landscape as well as the CLK Inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which indication is expected to grab the major CLK inhibitors market share @ CLK Inhibitors Market Report
Key Takeaways from the CLK Inhibitors Market Report
- In May 2025, Biosplice announced the first patient dosed in a Phase 2 clinical trial of cirtuvivint for advanced soft-tissue sarcomas. This multicenter, open-label trial in Spain will evaluate cirtuvivint monotherapy in about 30 patients with disease progression after standard treatment.
- In 2024, the United States accounted for the highest number of diagnosed prevalent cases of metastatic castration-resistant prostate cancer approximately 199,100.
- As per the estimates, in the US, the majority of the prostate cases were found to be localized/locally advanced cases (Stage I-III), comprising approximately 60% of total cases, while nearly 32% belonged to biochemical recurrence/ progressive cases.
- In the US, in 2024, there were approximately 204,800 new cases of NSCLC cancer, ~115,500 in men and ~89,300 in women.
- NSCLC is more common in males as compared to females. In the US, around 56% of males are diagnosed with NSCLC.
- Among the EU4 countries, the highest number of incident cases of colorectal cancer was observed in Germany in 2023, while Spain accounted for the lowest number of incident cases of colorectal cancer.
- The leading CLK inhibitor Companies, such as Curis, Aurigene Oncology, Chordia Therapeutics, Biosplice Therapeutics, and others.
- Promising CLK Inhibitors Therapies such as Emavusertib (CA-4948), CTX-712, Cirtuvivint (SM08502), and others.
Discover which indication is expected to grab the major CLK inhibitors market share @ CLK Inhibitors Market Report
CLK Inhibitors Overview
CLKs (Cdc2-like kinase) are dual specificity protein kinases that are involved in gene splicing regulation. The CLK family has four members, CLK1/STY, CLK2, CLK3, and CLK4. CLKs catalyze the phosphorylation of SR proteins, serine, and arginine-rich splicing factors 1-12 (SRSF1-12), which regulate the spliceosome molecular machinery. Compromised accuracy of alternative splicing can have a profound impact on human pathogenesis, in particular on tumor development and progression. Overexpression of active CLKs causes the redistribution of SR proteins within the nucleus and dissolution of speckles, dispersion of eIF4E nuclear speckles, complete redistribution of interchromatin granule clusters, and specific targeting of SRp55 for degradation by proteasome.
CLK Inhibitors Epidemiology Segmentation
- Total Cases in Selected Indications for CLK Inhibitors
- Total Eligible Patient Pool in Selected Indications for CLK Inhibitors
- Total Treated Cases in Selected Indications for CLK Inhibitors
Learn more about the CLK inhibitors @ CLK Inhibitors Analysis
- Cirtuvivint (SM08502): Biosplice Therapeutics
Cirtuvivint (SM08502), developed by Biosplice Therapeutics, selectively targets dysregulated alternative pre-mRNA splicing in cancer cells. By inhibiting CLK and DYRK kinases, it induces tumor-specific changes in splicing events, reducing the expression of oncogenic proteins. This precision minimizes the impact on healthy tissues. Cirtuvivint shows promise in treating various cancers, including metastatic castration-resistant prostate cancer, non-small cell lung cancer, colorectal cancer, heme malignancies, and specific solid tumors. Currently, Cirtuvivint is in Phase I in its developmental process for metastatic castration-resistant prostate cancer, non-small cell lung cancer, and colorectal cancer. Additionally, it is advancing towards IND enabling selected heme malignancies and additional solid tumors, demonstrating its potential across diverse cancer types.
- Lorecivivint (SM04690): Biosplice Therapeutics
Biosplice Therapeutics is advancing Lorecivivint as a potential therapy for knee, hip, and shoulder osteoarthritis, along with degenerative disc disease. This injectable small-molecule inhibitor of CLK and DYRK kinases has displayed encouraging outcomes in enhancing pain relief, functional capacity, and structural integrity. Biosplice Therapeutics, recently completed two Phase III trials, OA-07 long-term structure, pain and function study, and OA-21 short-term pain study. The final analysis of OA-07 results demonstrated statistically significant improvement in joint structure, WOMAC Pain, and WOMAC Function, highlighting the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis. Preliminary analysis of OA-21 short-term pain results did not achieve statistical significance. The company has also initiated various IND-enabling studies of Lorecivivint for diseases such as osteoarthritis of the hip, osteoarthritis of the shoulder, and degenerative disc disease.
- CTX-712: Chordia Therapeutics
CTX-712 is a first-in-class, orally available, highly potent, and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of RNA splicing. Preclinical data show that CTX-712 demonstrated anti-proliferative activity in in-vitro and in-vivo models derived from hematologic malignancies. A phase I study of CTX-712 was conducted to evaluate the safety and the preliminary efficacy of CTX-712 in patients with relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS).
CLK Inhibitor Market Outlook
The CLK Inhibitors market is expected to grow in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of CLK Inhibitors, and the increasing number of CLK inhibitors that are under clinical trials. CLK inhibitors offer a promising therapeutic avenue across a spectrum of diseases, ranging from various cancers like non-small cell lung cancer, colorectal cancer, ovarian cancer, metastatic castration-resistant prostate cancer, and acute myeloid leukemia to musculoskeletal conditions such as osteoarthritis of the hip, shoulder, and knee, as well as degenerative disc disease. Dysregulation of alternative pre-mRNA splicing, a common driver of tumor initiation, progression, and therapy resistance, underscores the significance of targeting CLK/DYRK kinases.
Discover more about CLK inhibitors in development @ CLK Inhibitors Clinical Trials
CLK Inhibitors Market Dynamics
The CLK inhibitors market is gaining attention due to the rising interest in alternative splicing as a therapeutic target. CLKs, particularly CLK1-4, regulate the phosphorylation of serine/arginine-rich (SR) proteins, which are essential in modulating pre-mRNA splicing. Abnormal splicing is implicated in several diseases, including cancers, neurodegenerative disorders, and metabolic syndromes. With increasing research into RNA biology and precision medicine, the pharmaceutical industry is exploring CLK inhibitors as potential treatments to correct or modulate splicing errors.
CLK Inhibitors Treatment Market
CLK inhibitors represent a promising strategy for correcting abnormal alternative pre-mRNA splicing observed in various cancers, such as non-small cell lung cancer and metastatic castration-resistant prostate cancer, as well as in musculoskeletal conditions like osteoarthritis and degenerative disc disease. Targeting CLK activity may offer a novel anti-cancer approach by modulating pre-mRNA splicing, particularly in cancers driven by MYC. Abnormal CLK expression and disrupted splicing patterns have been linked to multiple human diseases, positioning CLKs as emerging disease biomarkers. Specifically, CLK1 and CLK2 are overexpressed in several cancers, including breast, colorectal, prostate, and glioblastoma. Preclinical studies have demonstrated that CLK inhibitors can have therapeutic potential across a range of conditions, including neurodegenerative and inflammatory disorders, viral infections, and cancer.
To know more about CLK inhibitors clinical trials, visit @ CLK Inhibitors Treatment
Scope of the CLK Inhibitors Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Forecast Period- 2025-2034
- CLK Inhibitors Companies- Curis, Aurigene Oncology, Chordia Therapeutics, Biosplice Therapeutics, and others.
- CLK Inhibitors Therapies- Emavusertib (CA-4948), CTX-712, Cirtuvivint (SM08502), and others.
- CLK Inhibitors Therapeutic Assessment: CLK Inhibitors’ current marketed and emerging therapies
- CLK Inhibitors Market Dynamics: Conjoint Analysis of Emerging CLK Inhibitor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, CLK Inhibitors Market Access and Reimbursement
Explore More Insights of the Report @ CLK Inhibitors Market Size
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of CLK Inhibitor
4. Key Events
5. Market Forecast Methodology
6. CLK Inhibitor Market Overview at a Glance in the 7MM
7. CLK Inhibitor: Background and Overview
8. Treatment and Management
9. Target Patient Pool
10. Emerging Therapies
11. CLK Inhibitor: Seven Major Market Analysis
12. SWOT Analysis
13. KOL Views
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
